Tofacitinib

Hospital Pharmacy

Volumn 48, Issue 5, 2013, Pages 413-424

  Cada, Dennis ^a   Demaris, Kendra ^a   Levien, Terri ^a   Baker, Danial ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; FLUCONAZOLE; FOLIC ACID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN; TACROLIMUS; TOCILIZUMAB; TOFACITINIB;

ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; CELLULITIS; CLINICAL PHARMACOLOGY; CROHN DISEASE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULARY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG PACKAGING; DRUG SAFETY; DRUG SCREENING; DRUG TREATMENT FAILURE; DRUG UTILIZATION; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; ESOPHAGUS CANDIDIASIS; FOOD AND DRUG ADMINISTRATION; HERPES ZOSTER; HOSPITAL PHARMACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY TRANSPLANTATION; LATENT TUBERCULOSIS; LIPID BLOOD LEVEL; LYMPHOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PNEUMOCYSTOSIS; PNEUMONIA; PROTEIN BINDING; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RADIOACTIVITY; RECURRENT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84877637823     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4805-413     Document Type: Review

References (33)

1. Xeljanz [package insert]. New York: Pfizer Inc; November 2012.
2. Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol. 2011;29(6):467-468.
3. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513-526.
4. Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005;32(9):1650-1653.
5. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273-287.
6. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci. 2011;32(1):25-34.
7. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234-4243.
8. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo [published correction appears in Arthritis Rheum. 2012;64(5): 1487]. Arthritis Rheum. 2009;60(7):1895-1905.
9. Pfizer announces FDA acceptance for review of new drug application for tofacitinib for adult patients with moderately to severely active rheumatoid arthritis. Business Wire Web Site. http://www.businesswire.com/news/home/ 20111220005356/en/Pfizer-Announces-FDA-Acceptance-Review-Drug-Application. Published December 20, 2011. Accessed December 21, 2011.
10. Yazici Y, Regens AL. Promising new treatments for rheumatoid arthritis-the kinase inhibitors. Bull NYU Hosp Jt Dis. 2011;69(3):233-237.
11. Tofacitinib. Drug Facts and Comparisons. Facts & Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health; 2012. Accessed December 7, 2012.
12. Tofacitinib. ClinicalTrials.gov website. http://www.clinicaltrials. gov. Accessed December 11, 2012.
13. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7:41.
14. Hutmacher MM, Krishnaswami S, Kowalski KG. Exposureresponse modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn. 2008;35(2):139-157.
15. Gupta P, Stock TC, Wang R, et al. A phase 1 study to estimate the absolute bioavailability of tofacitinib (CP-650,550) in healthy subjects [abstract 122902]. J Clin Pharmacol. 2011;51(9):1348.
16. Prakash C, Lin J, Chan G, Boy M. Metabolism, pharmacokinetics and excretion of a Janus kinase-3 inhibitor, CP-690,550, in healthy male volunteers [abstract]. AAPS J. 2008; 10:2492.
17. Lawendy N, Krishnaswami S, Wang R, et al. Effect of CP-690,550, an orally active Janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol. 2009; 49(4):423-429.
18. Chow V, Krishnaswami S, Chan G. Pharmacokinetics of CP-690,550, a Janus kinase inhibitor, in subjects with impaired renal function and end-stage renal disease [abstract PII-86]. Clin Pharmacol Ther. 2009;85:S63.
19. Lawendy N, Chan G,Wang R, Lamba M, Krishnaswami S. The effect of mild to moderate hepatic impairment on the pharmacokinetic of tasocitinib (CP-650,550) [abstract]. Clin Pharmacol Ther. 2011;89:S93.
20. Fleischmann R, Kremer J, Cush J, et al; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. New Engl J Med. 2012;367(6):495-507.
21. US Food and Drug Administration Advisory Committee Meeting. Tofacitinib for the treatment of rheumatoid arthritis: NDA 203214 briefing document. Food and Drug Administration Web site. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/ UCM302960.pdf. Published May 9 2012. Accessed November 9, 2012.
22. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIB dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64(3):617-629.
23. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIB dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and methotrexate alone. Arthritis Rheum. 2012;64(4):970-981.
24. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63(8):1150-1158.
25. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. New Engl J Med. 2012;367(6):508-519.
26. Strand V, Kremer JM, Li S, et al. Tofacitinib (CP-690,550) in combination with traditional disease-modifying anti-rheumatic drugs: phase 3 study patient-reported outcomes in patients with active rheumatoid arthritis and an inadequate response to disease-modifying anti-rheumatic drugs [abstract]. Arthritis Rheum. 2011;63(11):S1032.
27. Pfizer announces detailed results of ORAL Sync showing investigational compound tofacitinib reduces signs and symptoms and improves physical function in patients with moderateto-severe active rheumatoid arthritis, with results seen as early as two weeks [news release] New York: Pfizer Inc; May 24 2011. http://www.evaluatepharma.com/Universal/View.aspx? type5Story&id5245880. Accessed January 4, 2012.
28. Arthritis Advisory Committee Meeting. NDA 20314: tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had inadequate response to one or more disease-modifying anti-rheumatic drugs. US Food and Drug AdministrationWeb site. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ArthritisAdvisoryCommittee/UCM302958.pdf. Published May 9, 2012. Accessed November 9, 2012.
29. Chow V, Ni G, LaBadie R, Chan G. Open label study to estimate the effect of fluconazole on the pharmacokinetics of a JAK3 antagonist (CP-650,550) [abstract]. Clin Pharmacol Ther. 2008;83:S36.
30. Krishnaswami S, Kudlacz E, Yocum S, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of CP-690,550, a Janus kinase inhibitor [abstract]. AAPS J. 2009; 11:36.
31. Chow V, Wilkinson B, LaBadie R, et al. Open label study of the pharmacokinetics of a JAK3 antagonist (CP-690,550) and single doses of oral methotrexate in rheumatoid arthritis subjects [abstract]. Clin Pharmacol Ther. 2008;83:S36.
32. Rosebraugh CJ. NDA approval letter: Xeljanz (tofacitinib NDA 203214). US Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda- docs/appletter/2012/203214Orig1s000ltr.pdf. Published November 6, 2012. Accessed December 12, 2012.
33. Multimedia: US Food and Drug Administration approves Pfizer's Xeljanz (tofacitinib citrate) for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate [news release]. New York: Pfizer Inc; November 7, 2012. http://press.pfizer.com/press-release/multimedia-us-food-and-drugadministration- approves-pfizers-xeljanz-tofacitinib-citrat. Accessed November 20, 2012.